A Bridging Study of FB2001 in Healthy Subjects

Summary

In the first human clinical trial conducted in the United States, single and multiple dosing of FB2001 in multiple dose groups were partially completed，and FB2001 demonstrated good safety and tolerability. The bridge study of FB2001 will be conducted in China to evaluated the safety and PK of FB2001 in healthy Chinese population. This is a randomized, double-blind, placebo-controlled study of single and multiple dosing.

Timeline

Start

2021-12-29

Primary completion

2022-04-27

Completion

2022-06-02

Drugs

Indications